An angel network based out of the North Eastern United States looks to make equity investments in early-stage and selectively seed stage life science companies ranging from $.5 – $1.5 million. The firm is also open to syndication on larger deals will consider opportunities throughout the United States and Canada. The firm plans to allocate to 10 new companies over the next year.
The group is open to sectors in the life science space including therapeutics, diagnostics and medical devices. The firm is generally opportunistic in terms of technology type, indication and is open to both small molecules and biologics. The firm is comfortable in investing in series A, B, C, or D rounds and is willing to invest in technologies that are pre-clinical or in early clinical trials.
The is most interested in investing in companies with experienced management teams though they also consider spinouts from universities in certain situations. The firm looks to invest in privately held companies and generally takes a seat on the company’s board.
Next Phase Newsletter 
Leave a comment